The rise of GLP-1 weight-loss drugs has arguably been the second-hottest trend in the stock market right now — second to generative artificial intelligence (AI). Undoubtedly, the “GLP-1 run” has brought a great deal of enthusiasm to the biotechnology and healthcare scenes. However, I don’t expect it’ll be the last ground-breaking innovation from the health space over the coming years. As AI and biotech join forces, there’s no telling where the healthcare scene could be headed next. In any case,
Tirzepatide is already approved under the brand name Mounjaro (Lilly) to be used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.
Pharmaceutical behemoths Eli Lilly and Novo Nordisk will soon begin clinical trials for blockbuster obesity drugs in children as young as six years old.
/PRNewswire/ The "The U.S. Medical Weight Loss Market" report from Marketdata LLC has been added to ResearchAndMarkets.com s offering. The $8.8 billion U.S..